Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sangamo Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SGMO
Nasdaq
8731
https://www.sangamo.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sangamo Therapeutics Inc
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
- Mar 25th, 2024 6:52 pm
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
- Mar 22nd, 2024 12:05 pm
Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations
- Mar 14th, 2024 1:26 pm
Q4 2023 Sangamo Therapeutics Inc Earnings Call
- Mar 14th, 2024 11:23 am
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Mar 13th, 2024 12:05 pm
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
- Mar 13th, 2024 12:01 pm
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
- Mar 12th, 2024 10:30 pm
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
- Feb 12th, 2024 1:05 pm
With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners
- Feb 12th, 2024 1:02 pm
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
- Feb 5th, 2024 11:01 pm
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
- Nov 21st, 2023 1:49 pm
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript
- Nov 3rd, 2023 9:03 pm
Sangamo to cut jobs again with planned business overhaul
- Nov 2nd, 2023 12:15 pm
Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update
- Nov 1st, 2023 11:05 pm
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
- Nov 1st, 2023 8:01 pm
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Oct 26th, 2023 2:02 pm
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
- Oct 25th, 2023 8:15 pm
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
- Oct 24th, 2023 6:01 am
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
- Sep 20th, 2023 8:15 pm
Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past year
- Sep 4th, 2023 5:52 pm
Scroll